Skip to main content
SMFM 2026 Pregnancy Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared outside of the session
Faculty have requested this content not be shared outside of the session
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording available 2/16-5/2
Recording available 2/16-5/2
AIUM Credit
AIUM Credit
Foundation Awardee
Foundation Awardee
Poster Icons
Abstract Award
Abstract Award
Foundation Awardee
Foundation Awardee

Poster Session 4

Category: Clinical Obstetrics

Poster Session 4

(1008) Does buprenorphine administered for OUD improve stimulant abstinence in those with concomitant Stimulant Use Disorder

Thursday, February 12, 2026
3:30 PM - 5:00 PM  
Objective:
To evaluate if buprenorphine for opioid use disorder (OUD) decreases stimulant use in pregnant persons with a concomitant Stimulant Use Disorder (StUD).

Study Design:
Prospective cohort study of pregnant patients receiving prenatal care through a comprehensive perinatal substance use treatment program between 2014 and 2025. All patients with OUD were offered MOUD primarily with buprenorphine. The study group was comprised of patients with both OUD and StUD who were prescribed buprenorphine, compared to control patients not receiving MOUD. The primary outcome was abstinence from stimulant use based on confirmatory urine drug screens (UDS) obtained during prenatal visits and at delivery. Fisher’s exact test was used for categorical variables, and two sample t-tests or Poisson regression were used to calculate p-values as appropriate for quantitative variables.

Results:
260 patients participated in prenatal care while on buprenorphine for MOUD with a co-occurring StUD, compared to 33 patients not receiving MOUD in the setting of OUD and StUD. There were no significant differences in demographics between groups with respect to age, race, insurance, tobacco use or psychiatric diagnosis, except that p</span>atients in the no MOUD group were more likely to have experienced PTSD, 41% v 16%, p= 0.0028. During prenatal care, 36% of UDS’ were positive for cocaine or methamphetamine for the no MOUD group compared to 18% for those on MOUD, p=0.0042. Patients receiving MOUD attended more prenatal visits, 5 (3-11) v 9 (4-16), p=0.0236. There was no significant difference in neonatal birthweight, 3045g +/- 556 v 2944g +/- 571, p=0.4218, or treatment days for Neonatal Opioid Withdrawal Syndrome, 17 (13.8-25.5) v 14 (11.0-22.0), p=0.2039. UDS at delivery demonstrated cocaine positive rate of 15% v 5% for those not on MOUD, compared to those on MOUD, p=0.039.

Conclusion:
Buprenorphine is a safe and effective medication used to treat OUD during pregnancy. It may also provide some benefit for concomitant StUD during pregnancy by decreasing stimulant use and increasing engagement with prenatal care. Further studies are needed.